Embedded within this has been the recognition that FTD and ALS are increasingly recognized to share not only a clinical phenotypic spectrum, but also an underlying pathobiology as reflected not only in alterations in the metabolism of TDP-43, but increasingly in the metabolism of tau. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.